Momentum Bioscience Limited, a Reading, UK-based Medtech company, has closed a £230k round.
This includes £180k from LBA investors, which made the investment through the LBA EIS RoundTable Syndicate Fund 2011, and significant investment from management
The company plans to use the funds to funding to conduct clinical trials for its prototype products prior to completing product development and launch.
Led by Chairman David Evans and CEO Bill Mullen, Momentum Bioscience is developing a suite of related technologies collectively termed Enzyme Mediated Amplification (EMA), for the rapid detection of infection in blood and other normally sterile body fluids and all living bacteria and fungi.
FinSMEs
26/09/2011